Previstage GCC Colorectal Cancer Staging Test study to be presented at 2013 ASCO Annual Meeting

May 16 2013

New findings validate clinical utility in Colorectal Cancer Staging

DiagnoCure Inc. (TSX: CUR) (OTCQX: DGCRF) (the "Corporation"), today announced that results from a large validation study of the Previstage^TM GCC Colorectal Cancer Staging Test have been selected for presentation at the 2013 American Society of Clinical Oncology^® (ASCO^®) Annual Meeting, taking place in Chicago, Illinois from May 31 to June 4, 2013. The results of the second phase of the VITAR (Validating Indicators To Associate Recurrence Risk) study, which included 463 untreated stage II (T3N0) colon cancer patients from North American and European clinical sites will be presented during this annual meeting. These patients had not been treated with adjuvant chemotherapy mainly because their lymph nodes appeared cancer‐free by examination under the microscope, yet 10% of them had a disease recurrence or died from cancer afterwards.

The presentation titled "Guanylyl cyclase C (GCC) expression in lymph nodes (LNs) as a determinant of recurrence in stage II colon cancer (CC) patients (pts)" (Abstract #3639), will be exhibited on Sunday, June 2, 8:00 AM - 11:45 AM, S Hall A2.

"Our new study supports the prognostic value of our Previstage^TM GCC assay independently of traditional histopathology risk factors. In order to establish a risk of recurrence for the stage II patients, the study focused on the positive LN ratio (LNR), defined as the number of nodes in which cancer cells were identified with the Previstage^TM GCC test, divided by the total number of nodes examined," said Dr Yves Fradet , President and Chief Medical Officer of DiagnoCure. "We believe that Previstage^TM GCC has the potential to improve management of untreated stage II colon cancer."